Chemical industry – Page 80
-
Business
Hospira buyout is a shot in the arm for Pfizer’s biosimilars
$17bn deal, intended to bolster sterile injectable and biologics capabilities, will be financed with existing cash and new debt
-
Business
WR Grace to split in half
Two daughter companies will focus on catalysts and speciality construction chemicals
-
Business
Tronox to buy FMC’s alkali chemicals
$1.6bn deal helps Tronox strengthen its inorganics portfolio as FMC shifts towards agrochemicals
-
Business
Fatal blast at Indian chemical plant
One worker killed and four injured at Survival Technologies plant in Ankleshwar
-
Business
EU regulator calls for generic drug suspensions
The EMA wants hundreds of formulations off the market after identifying systematic fraud in a major Indian contract clinical research organisation
-
BusinessRoche chases bolt-on acquisitions as it pushes into genomics
Company’s recent shopping spree aims to harness genome sequencing to advance personalised treatments
-
Business
UK calls for fracking restrictions
Environment committee wants to protect national parks and tighten regulation
-
Business
Shire deepens rare disease focus with NPS buyout
Approval of parathyroid hormone drug further validates acquisition decision
-
Business
US methane emissions reduction effort generates sparks
White House targets oil and gas sector but gets a chilly reception from Republican lawmakers and industry
-
Business
MFG Chemical fined after worker dies
Company cited for multiple safety failings before the fatal incident
-
Business
Ansun settles fraud case for $2m
Executives fiddled timesheets to overcharge US funding agency on grants and research contracts
-
Business
Biogen Idec to buy Convergence for pain pipeline
UK firm will remain intact as a ‘centre of excellence’ in pain R&D for Biogen
-
-
BusinessUS poised to approve its first ‘biosimilar’ drug
FDA panel recommends Sandoz’s copy of Amgen’s Neupogen
-
-
BusinessRevlon’s former chief scientist claims he was fired over safety whistleblowing
Ex-employee sues firm alleging job loss was the result of raising safety concerns that the company’s chief executive didn’t want to hear
-
-
Business
EU recommends Parkinson’s drug for approval
First new molecule for a decade, but Alzheimer’s still posing challenges as antibody treatment withdrawn from trials
-
Business
EU chemicals regulator scolded over animal testing
Ombudsman says ECHA isn’t doing enough to require alternative, non-animal methods
-
Business
Consumer products firms fined for French price fixing
€950m fines for ‘friends clubs’ that pushed up prices for home and personal care products